REVEAL-CKD: Prevalence and consequences of undiagnosed chronic kidney disease

Trial Identifier: D169AR00003
Sponsor: AstraZeneca
NCTID:: NCT04847531
Start Date: December 2020
Primary Completion Date: November 2023
Study Completion Date: November 2023
Condition: Chronic Kidney Diseases

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Australia, NSW Sydney, NSW, Australia, 2040
Brazil Sao Paulo, Brazil, 05403-000
Canada, Ontario Kingston, Ontario, Canada, K7L 3G2
China, Guangdong Guangzhou, Guangdong, China, 510515
France Boulogne-Billancourt, France, 92641
Germany Frankfurt, Germany, 60549
Italy Milan, Italy, 20124
Japan Kyoto, Japan, 604-0086
Spain Madrid, Spain, 28037
UK, Greater London London, Greater London, UK, E14 4PU
United States, Kentucky Louisville, Kentucky, United States, 40202
United States, Massachusetts Cambridge, Massachusetts, United States, 02140
United States, Michigan Ann Arbor, Michigan, United States, 48108